DNA vaccines
Achieving a robust immune response is vital for vaccine development, our synthetic hpDNA technology offers a promising alternative to plasmid DNA. Bacterial sequences, antibiotic resistance genes and host cell contaminants are absent in the hpDNA constructs, ensuring a higher level of safety and regulatory compliance for DNA vaccine development.
hpDNA works in synergy with our Hermes®, non-viral delivery platform, helping drive stronger gene expression compared to plasmid DNA. It is also fully compatible with a variety of other gene delivery technologies, including electroporation (EP) and LNPs, giving you flexibility when developing your DNA vaccines.
hpDNA
hpDNA is a double stranded linear DNA, covalently closed with single strand hairpins at the 5’ and 3’ ends. Ideal for DNA vaccines and non-viral applications.
Benefits of using hpDNA
No bacterial backbone elements improve safety and compliance
Dose reduction compared to plasmid DNA due to absence of unnecessary backbone sequences
Synergy with Hermes® non-viral delivery platform with formulations optimised for hpDNA encapsulation
Accelerated timelines, ideally suited for personalized immunotherapy or pandemic response
Suitable for complex sequences, such as high GC content
What we offer
Rapid synthesis of custom hpDNA constructs up to 20 kb for use in DNA vaccine applications
Specialized team to support with LNP platform
Available in RUO, HQ and GMP grade
Technology
Find out more about our enzymatic manufacturing process and the benefits of synthetic DNA.
Manufacturing
Discover our RUO, HQ, and GMP-grade synthetic DNA, designed for every stage from discovery to commercial production.